Inhaled siRNA Formulations for Respiratory Diseases: From Basic Research to Clinical Application

Yulin Fan, Zhijun Yang*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

Abstract

The development of siRNA technology has provided new opportunities for gene-specific inhibition and knockdown, as well as new ideas for the treatment of disease. Four siRNA drugs have already been approved for marketing. However, the instability of siRNA in vivo makes systemic delivery ineffective. Inhaled siRNA formulations can deliver drugs directly to the lung, showing great potential for treating respiratory diseases. The clinical applications of inhaled siRNA formulations still face challenges because effective delivery of siRNA to the lung requires overcoming the pulmonary and cellular barriers. This paper reviews the research progress for siRNA inhalation formulations for the treatment of various respiratory diseases and summarizes the chemical structural modifications and the various delivery systems for siRNA. Finally, we conclude the latest clinical application research for inhaled siRNA formulations and discuss the potential difficulty in efficient clinical application.
Original languageEnglish
Article number1193
Number of pages27
JournalPharmaceutics
Volume14
Issue number6
DOIs
Publication statusPublished - 2 Jun 2022

Scopus Subject Areas

  • Pharmaceutical Science

User-Defined Keywords

  • clinical application
  • delivery systems
  • drug delivery barriers
  • inhaled siRNA formulations
  • respiratory diseases
  • structural modification

Fingerprint

Dive into the research topics of 'Inhaled siRNA Formulations for Respiratory Diseases: From Basic Research to Clinical Application'. Together they form a unique fingerprint.

Cite this